• Osteopore partners with Tan Tock Seng Hospital to develop a novel implant for treating avascular necrosis (AVN)
• The collaboration is funded by a SGD 50,000 MedTech grant from NHG Health
• The total market opportunity for AVN treatment is projected to reach USD 10.2 billion by 2030

Osteopore Limited, an Australian-Singaporean regenerative medicine company, has announced a co-development collaboration with Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, for the development of a novel implant used in the treatment of avascular necrosis (AVN) at the hip joint. The collaboration is funded by a SGD 50,000 MedTech grant from NHG Health and led by Principal Investigator (PI) Dr Michael Yam Gui Jie, a Consultant from the Department of Orthopaedic Surgery, and Clinical Director of the Medical 3DP Centre at TTSH. AVN is a condition where blood supply is interrupted, leading to necrosis of bone tissue, predominantly at the hip joint. If left untreated, it can result in the collapse of the bone at the hip joint, requiring total hip replacement as the most effective treatment. Under the collaboration, Osteopore will work with Dr Yam to design and perform the necessary tests to arrive at a proof-of-concept for a novel implant that enhances outcomes for core decompression in AVN of the hip. The collaboration runs for a period of 12 months starting September 2025, and ends with potential first-in-human milestones. The total market opportunity of AVN treatment is projected to reach USD 10.2 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 8.5% between 2023 and 2030, driven by the growing prevalence of AVN, increasing awareness, and earlier diagnosis.

The collaboration with TTSH has the potential to expand Osteopore's product offering in orthopaedics and strengthen the company's collaboration with commercial partners such as DKSH, which distributes Osteopore's products in Singapore. The company will provide timely updates to the market on the progress of this project.